

Prescient Therapeutics Launches Share Purchase Plan to raise \$8.0 million

Key highlights:

- Prescient Therapeutics targeting to raise \$8.0 million via a Share Purchase Plan at \$0.175 per share (14.6% discount to 5 day VWAP).
- Funds raised will be used to progress the Company's deep pipeline of innovative cancer therapies, namely the ongoing clinical development of its targeted therapies PTX-100 and PTX-200, and progressing its innovative cell therapies towards and into first-in-human clinical studies.
- Join CEO and MD Steven Yatomi-Clarke for a live shareholder briefing on Tuesday 30th August at 12pm (AEST). [Register here](#).

MELBOURNE Australia, 24 August 2022 – Prescient Therapeutics (ASX: PTX), a clinical stage oncology company developing personalised therapies to treat cancer, is pleased to announce a Share Purchase Plan (**SPP**) targeting to raise \$8.0 million. Funds raised will be used to progress Prescient's deep pipeline of innovative cancer therapies, namely the ongoing clinical development of its targeted therapies PTX-100 and PTX-200, and progressing its innovative cell therapies towards and into first-in-human clinical studies. Funds will also go towards general working capital and costs of the offer.

Under the SPP new fully paid ordinary shares will be issued at \$0.175 per share, equivalent to a 14.6% discount to the volume weighted average price (**VWAP**) over the five trading days before the date the SPP was announced, and a 16.7% discount to the close price on 23 August 2022.

The Company will offer Eligible Shareholders who were registered shareholders as at 5:00pm (AEST) on Tuesday 23rd August 2022 (**Record Date**) the opportunity to apply for up to A\$30,000 of new fully paid ordinary shares (**New Shares**) in the Company under the SPP. Full details of the SPP will be set out in the SPP Offer Booklet which is expected to be released to the ASX and despatched to eligible shareholders within five business days.

Prescient CEO & Managing Director, Steven Yatomi-Clarke commented: "The last couple of years in particular have been a period of incredible growth and progress for Prescient, and the Company is seeking to maintain this momentum and its position at the forefront of oncology innovation. The Prescient Board acknowledges, values and thanks shareholders for their continued support of the Company. We are pleased to provide our shareholders with the opportunity to participate in this SPP by purchasing

additional shares at a modestly discounted price without incurring brokerage or transaction costs. Funds raised will assist the Company to progress its clinical and pre-clinical programs along with providing general working capital.

Prescient continues to build out a diverse and innovative pipeline of personalised therapies for cancer.”

Participate in the Share Purchase Plan

Shareholders can request an electronic copy of their personalised Share Purchase Plan application form be emailed to them as soon as available from the below link:

<https://prescienttherapeutics.investorportal.com.au/request-SPP/>

Reach Corporate are the advisers managing the Share Purchase Plan Offer and can be contacted by calling 1300 805 795 or via advisers@reachmarkets.com.au

Share Purchase Plan Timetable

An indicative timetable of key dates is detailed below. This timetable may change at the discretion of the Company, subject to the requirements of the ASX Listing Rules.

Event	Indicative Date
Record Date	23 August 2022
Announcement of SPP Offer	24 August 2022
SPP Opens & Despatch of SPP Offer Booklet	24 August 2022
SPP Closes	5pm AEST, Wednesday, 28 September 2022
SPP results announced to the ASX	3 October 2022
Issue of Shares under SPP	5 October 2022
Trading of all SPP Shares (subject to ASX Listing Rules)	6 October 2022
Despatch of holding statements to Eligible Shareholders participating in the SPP	13 October 2022

In accordance with the instructions in the SPP booklet the only action required is to transfer the funds for the amount you would like to invest in this Offer, using your Unique Reference Number, via BPAY or Electronic Funds Transfer (EFT). The action of paying the funds via either of these methods will constitute acceptance of the Offer. Acceptances and payment must be received by the Company’s registry, Automic, before 5pm (AEST) on Wednesday 28 September 2022.



Join a shareholder briefing

Join CEO and MD of Prescient Therapeutics, Steven Yatomi-Clarke, for a live and interactive shareholder briefing on Tuesday 30th August at 12pm (AEST) where he will discuss the Share Purchase Plan, use of funds and how to participate. [Register here](#).

- Ends -

To stay updated with the latest company news and announcements, [please update your details](#) on our investor centre.

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Cell Therapies

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Prescient is developing OmniCAR programs for next-generation CAR-T therapies for Acute Myeloid Leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (GBM).

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it has shown encouraging efficacy signals and safety.



PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects. This highly promising compound is currently in a Phase 1b/2 trial in relapsed and refractory AML, where it has resulted in 4 complete remissions so far. PTX-200 previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer.

Find out more at www.ptxtherapeutics.com or connect with us via Twitter [@PTX_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](#).

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries

Steven Yatomi-Clarke
CEO & Managing Director Prescient
Therapeutics
steven@ptxtherapeutics.com

Investor enquiries

Sophie Bradley
Reach Markets
+61 450 423 331
ir@reachmarkets.com.au

Media enquiries

Andrew Geddes
CityPR
+61 2 9267 4511
ageddes@citypublicrelations.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as



we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website: [Supplemental COVID-19 Risk Factors](#)